全膝关节置换术后使用氨甲环酸血液保护不优于ε-氨基己酸
这项前瞻性随机对照试验将194例初次单侧全膝关节置换患者随机分为静脉ε-氨基己酸组(n=96)和氨甲环酸组(n=98),患者和术者均设盲。氨甲环酸组平均估计失血量少于ε-氨基己酸组(均差144.2 mL,95%CI 13.62至274.78 mL,p=0.031),但两组均无需输血,血红蛋白变化、血清肌酐变化、术后并发症和住院时长均无显著组间差异。作者认为ε-氨基己酸可能是氨甲环酸可接受的替代选择,但需在非劣效性试验中重复验证。
要点
- 氨甲环酸组平均估计失血量少于ε-氨基己酸组(均差144.2 mL,95%CI 13.62至274.78 mL,p=0.031)。
- 两组均无需输血,血红蛋白变化、血清肌酐变化、术后并发症和住院时长无显著组间差异。
- 作者认为ε-氨基己酸可能是氨甲环酸可接受的替代选择,但需在非劣效性试验中重复验证。
核心结论
- 虽然ε-氨基己酸组估计失血量显著更多,但两组均无需输血,其他所有测量结局均无显著组间差异。
- 作者认为ε-氨基己酸可能是全膝关节置换术后血液保护中氨甲环酸可接受的替代选择,但需在非劣效性试验中重复验证。
研究设计与样本
- 前瞻性随机对照试验,共194例计划在同一社区医院接受初次单侧全膝关节置换的患者,随机接受静脉ε-氨基己酸(n=96)或氨甲环酸(n=98),患者和术者均设盲。
- 主要结局包括输血、估计失血量和血红蛋白下降;次要结局包括血清肌酐变化、术后并发症和住院时长。
- 证据等级:治疗性I级。
主要发现
- 氨甲环酸组平均估计失血量少于ε-氨基己酸组(t185=2.18,p=0.031;均差144.2 mL,95%CI 13.62至274.78 mL)。
- 两组均无需输血。
- 血红蛋白变化、血清肌酐变化、术后并发症和住院时长均无统计学显著或临床相关的组间差异。
关键数值与推荐
- 氨甲环酸组 vs ε-氨基己酸组:平均估计失血量均差144.2 mL(95%CI 13.62至274.78 mL,p=0.031),氨甲环酸组较少。
- 两组输血例数均为0。
临床怎么用
- 作者认为ε-氨基己酸可能是全膝关节置换术后血液保护中氨甲环酸可接受的替代选择,但需在非劣效性试验中重复验证。
局限性
- 作者指出需在非劣效性试验中重复其结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epsilon-aminocaproic acid (EACA) and tranexamic acid (TXA) are synthetic amino acid derivatives that interfere with fibrinolysis, promoting hemostasis by pharmacological means. Although both drugs have been shown to decrease blood loss with a minimal risk of thromboembolic adverse events following cardiac and vascular surgery, we are aware of only 1 published trial that directly compared the antifibrinolytic effects of EACA with those of TXA after total knee arthroplasty (TKA). The primary aim of this prospective, randomized, controlled trial was to determine whether TXA provides superior blood conservation following TKA compared with that provided by EACA. METHODS: A total of 194 patients scheduled to undergo a primary unilateral TKA in the same community-based hospital were prospectively randomized to receive intravenous EACA (n = 96) or TXA (n = 98). Both the patients and the operating surgeons were blinded to the treatment assignments. Primary outcome measures included transfusions, estimated blood loss, and the drop in the hemoglobin (Hgb) level. Secondary outcomes measures included the change in the serum creatinine level, postoperative complications, and length of hospital stay. RESULTS: Although the patients who received TXA averaged less estimated blood loss than the patients who received EACA (t185 = 2.18, p = 0.031; mean difference = 144.2 mL, 95% confidence interval = 13.62 to 274.78 mL), no transfusions were required in either group. We observed no statistically significant or clinically relevant between-group differences in the change in Hgb or serum creatinine level, postoperative complications, or length of hospital stay. CONCLUSIONS: Although the estimated blood loss was significantly greater in the EACA group, no transfusions were required and no significant between-group differences were observed for any other outcomes measured. We concluded that EACA may be an acceptable alternative to TXA for blood conservation following TKA, although replication of our results in noninferiority trials is necessary. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
引用
- Boese CK, Centeno L, Walters RW, et al. Blood Conservation Using Tranexamic Acid Is Not Superior to Epsilon-Aminocaproic Acid After Total Knee Arthroplasty. J Bone Joint Surg Am. 2017. PMID: 28976426. doi:10.2106/JBJS.16.00738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。